A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Clinical trial NCT06485219 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06485219
Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)

Start date: 2024-04-14
Primary completion: 2026-06-30
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.